Table 3.

Major treatment alternatives in 2014 according to GOLD 2017 groups by level of care.

	A		B		C		D
	PC	SC	PC	SC	PC	SC	PC	SC
No/other MT	54%	46%	35%	25%	27%	9%	19%	22%
Bronchodilator therapy	16%	16%	19%	17%	15%	13%	13%	15%
LABA + ICS	12%	12%	11%	13%	15%	8%	17%	11%
Triple inhaled therapy	18%	26%	35%	45%	43%	70%	51%	52%

Distribution of the three major recommended treatments over level of care. No/other includes patients with only rescue medication and with only ICS. Bronchodilator therapy includes maintenance treatment with long- or short-acting muscarinic antagonists and/or long-acting beta-2-agonists. GOLD = Global initiative for chronic Obstructive Lung Disease; PC = primary care; SC = secondary care; LABA = long-acting beta-2-agonists; ICS = inhaled corticosteroids; OR = odds ratio; CI = confidence interval; Ref = reference category